Remainder

Charles River stock falls nearly 10% on soft quarterly results

Charles River stock falls nearly 10% on soft quarterly results

By Zachary Brennan

Charles River Laboratories saw only slight growth in revenue compared to the same quarter last year, which was driven by its safety assessment and endotoxin and microbial detection businesses, and double-digit revenue increases from mid-tier biotech clients.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers